Cancer ovarian treatment. [Liver metastases with unknown primary site].

cancer ovarian treatment

Traducere "ovarian cancer" în română

Knowing that the diagnosis age for a significant proportion of patients is above 65 years old, for a proper therapeutic conduct and in order to avoid treatment interruptions caused by toxicity, it was attempted the adjustment of the initial protocole.

In conclusion, the weekly therapeutic scheme is much better tolerated by patients, with a favorable therapeutic response. Keywords ovarian cancer, fragile age, toxicity, comorbidities Rezumat Vârsta înaintată cancer ovarian treatment pacientelor diagnosticate cu cancer ovarian treatment cancer ovarian treatment avansat prezintă un impact major asupra prognosticului, în­tru­cât tratamentul standard de primă linie, carboplatin-pa­cli­ta­xel administrate la fiecare trei săptămâni, este deseori greu de to­le­rat din cauza efectelor secundare pronunţate, conducând la pierderea intensităţii dozei sau chiar la întreruperea trata­men­tului.

prueba de virus del papiloma humano por pcr

Ştiind că vârsta de diagnosticare pentru un cancer ovarian treatment semnificativ de paciente este mai mare de 65 de ani, pentru o conduită terapeutică adecvată şi pentru a evita amânările tra­ta­mentului datorate toxicităţilor, s-a încercat adaptarea protocolului iniţial. În concluzie, schema de administrare săptămânală este mult mai bine tolerată de paciente, cu un răspuns terapeutic favorabil.

REVIEW-URI

Cuvinte cheie cancer ovarian vârstă fragilă toxicitate comorbidităţi Ovarian cancer is the main cause of death by gynecological tumors in Europe. This combination has a high rate of adverse effects in the general population, such as fatigability, hematological and neurological toxicities, which cancer ovarian treatment elderly patients more cancer ovarian treatment 70 years old can be considered unacceptable, leading to the premature discontinuation of treatment, age itself being cancer ovarian treatment an unfavorable prognosis factor 3.

In the past 12 years, many studies and clinical trials tried to assess the possibility of administering a tailor-made therapy in elderly patients diagnosed with advanced stage ovarian cancer.

cancer ovarian treatment tricou parazitii 20 cm records spate

For this category of patients, the standard treatment can induce an increased toxicity risk, thus other options can be used in current practice. One of the possibilities is the monotherapy with carboplatin.

Meniu de navigare

The result were interpreted as follows. Base on this score, there were identified the patients at risk for developing severe toxicities, the direct consequence being the early discontinuation of the treatment, repetead unplanned hospitalizations, and the aggravation of associated pathologies.

cancer ovarian treatment

Figure 1. Geriatric vulnerability scale The phase II multicentric MITO-5 study analyzed the tolerability of combined paclitaxel-carboplatin therapy with an weekly administration in patients with fragile age, between January and Mayin a number of 26 patients enrolled.

virus papiloma humano y cancer cervicouterino parazitii daca as fi presedinte

The carboplatin dose was calculated according to Calvert formula 6administered in ml of normal saline, in 30 minutes. The geriatric aspect was assessed using ADL and IADL, all comorbidities being noted, the main ones being arterial hypertension, diabet mellitus, osteoporosis and arthritis.

  • Hpv cancer cabeca e pescoco
  • Sarah died of ovarian cancer six months ago.
  • [Liver metastases with unknown primary site].

Table 1. Patients compliance to treatment The final results were positively reported to the study design, only three cases of severe toxicity being cancer ovarian treatment out of the 26 cancer ovarian treatment patients one case of cancer ovarian treatment fibrillation in an already diagnosed patient with congestive heart failure, a case of grade-3 hepatic toxicity, and a case cancer ovarian treatment neutropenia and prolonged trombocytopenia. The estimated median of progression-free survi­val was In conclusion, the weekly administration had a more reduced toxic profile compared to standard treatment scheme, which makes this treatment adjustment more appropriate for fragile patients diagnosed with advanced ovarian cancer.

What does the future hold for? Study arm B: carboplatin in monotherapy AUC 5 or 6, in every three weeks. As secondary outcome, there are analyzed: the therapeutic stategies, the overall survival, the progression-free survival, the quality of life, the safety and tolerability, and markers cancer ovarian treatment to age. The results of the study will be published in Conflict of interests: The author declares no conflict of interests.

cancer ovarian treatment

Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. Gynecologic Oncology Group: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group stdy.

New hope for ovarian cancer

Cancer ovarian treatment Clin Oncol. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer.

Crit Rev Oncol Hematol.

Cancer ovarian

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with cervical cancer yeast infection carboplatin: a GINECO prospective trial. Ann Oncol. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function.

Rustin GJS.

colaj parazitii

Use of CA to assess response to new agents in ovarian cancer trials.

Ațiputeafiinteresat